To increase the therapeutic efficacy in HER2+ cancer cells, Farasat et al. [79] showed that a combination of four anti-HER2 NBs targeting various HER2 epitopes could be coupled on doxorubicin-loaded PEGylated liposomes (Figure 2E). The gene discussed is ERBB2; the disease is cancer.